Research
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo
November 17, 2026 • Source: Nature Biotechnology
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo
**Weekly Intelligence Dispatch (2026-11-17):** A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo (Source: Nature Biotechnology).
Technical & Enterprise R&D Implications
A CD7-targeted AAV variant enables efficient T and NK cell engineering in vivo Enterprise buyers and technical leads tracking Research can verify full primary documentation via Nature Biotechnology.
Published November 17, 2026
More NewsLast updated: November 17, 2026
